Tags

Type your tag names separated by a space and hit enter

Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.NN

Abstract

Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients. In this secondary analysis of data from the CONFIRMS trial, we found that among 374 older subjects, urate-lowering therapy with approved doses of febuxostat or commonly prescribed doses of allopurinol was at least comparable to that in 1894 younger subjects and was well tolerated despite high rates of renal impairment and cardiovascular comorbidities in the older subjects.

Authors+Show Affiliations

University of Chicago, Pritzker School of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA. mbecker@medicine.bsd.uchicago.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22132950

Citation

Becker, Michael A., et al. "Treating Hyperuricemia of Gout: Safety and Efficacy of Febuxostat and Allopurinol in Older Versus Younger Subjects." Nucleosides, Nucleotides & Nucleic Acids, vol. 30, no. 12, 2011, pp. 1011-7.
Becker MA, MacDonald PA, Hunt B, et al. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1011-7.
Becker, M. A., MacDonald, P. A., Hunt, B., & Gunawardhana, L. (2011). Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides, Nucleotides & Nucleic Acids, 30(12), 1011-7. https://doi.org/10.1080/15257770.2011.603715
Becker MA, et al. Treating Hyperuricemia of Gout: Safety and Efficacy of Febuxostat and Allopurinol in Older Versus Younger Subjects. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1011-7. PubMed PMID: 22132950.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. AU - Becker,Michael A, AU - MacDonald,Patricia A, AU - Hunt,Barbara, AU - Gunawardhana,Lhanoo, PY - 2011/12/3/entrez PY - 2011/12/3/pubmed PY - 2012/3/22/medline SP - 1011 EP - 7 JF - Nucleosides, nucleotides & nucleic acids JO - Nucleosides Nucleotides Nucleic Acids VL - 30 IS - 12 N2 - Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients. In this secondary analysis of data from the CONFIRMS trial, we found that among 374 older subjects, urate-lowering therapy with approved doses of febuxostat or commonly prescribed doses of allopurinol was at least comparable to that in 1894 younger subjects and was well tolerated despite high rates of renal impairment and cardiovascular comorbidities in the older subjects. SN - 1532-2335 UR - https://www.unboundmedicine.com/medline/citation/22132950/Treating_hyperuricemia_of_gout:_safety_and_efficacy_of_febuxostat_and_allopurinol_in_older_versus_younger_subjects_ L2 - https://www.tandfonline.com/doi/full/10.1080/15257770.2011.603715 DB - PRIME DP - Unbound Medicine ER -